CVRx (NASDAQ:CVRX) Downgraded to “Hold” Rating by Craig Hallum

Craig Hallum lowered shares of CVRx (NASDAQ:CVRX) from a buy rating to a hold rating in a report released on Friday, MarketBeat.com reports. They currently have $4.00 price target on the stock.

Other equities research analysts also recently issued research reports about the company. Wall Street Zen upgraded CVRx from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Lake Street Capital lowered CVRx from a “buy” rating to a “hold” rating and set a $3.50 target price on the stock. in a research note on Friday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CVRx in a report on Monday. Piper Sandler downgraded CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price target for the company. in a research report on Friday. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $10.00 price objective on shares of CVRx in a report on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, CVRx has an average rating of “Hold” and a consensus target price of $6.90.

CVRx Stock Performance

CVRx stock opened at $2.39 on Friday. CVRx has a 1-year low of $2.30 and a 1-year high of $11.30. The company has a current ratio of 10.20, a quick ratio of 8.89 and a debt-to-equity ratio of 2.01. The firm has a market capitalization of $63.43 million, a PE ratio of -1.21 and a beta of 0.81. The firm’s 50 day simple moving average is $5.19 and its 200 day simple moving average is $6.49.

CVRx (NASDAQ:CVRX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.01). The firm had revenue of $15.71 million during the quarter, compared to the consensus estimate of $15.55 million. CVRx had a negative net margin of 84.93% and a negative return on equity of 133.84%. As a group, analysts expect that CVRx will post -1.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Larson Financial Group LLC increased its stake in CVRx by 155.6% in the fourth quarter. Larson Financial Group LLC now owns 5,426 shares of the company’s stock valued at $39,000 after acquiring an additional 3,303 shares during the last quarter. R Squared Ltd purchased a new position in shares of CVRx in the 4th quarter worth about $74,000. Aaron Wealth Advisors LLC bought a new position in shares of CVRx during the 1st quarter valued at about $101,000. Virtu Financial LLC bought a new position in shares of CVRx during the 4th quarter valued at about $79,000. Finally, Corient Private Wealth LLC purchased a new position in shares of CVRx during the 4th quarter valued at about $81,000. 75.27% of the stock is currently owned by hedge funds and other institutional investors.

CVRx News Roundup

Here are the key news stories impacting CVRx this week:

• Positive Sentiment: CVRx reported second-quarter revenue of $15.71 million, slightly above the $15.55 million analyst consensus. Its per-share loss of $0.53 was also an improvement from a $0.57 loss a year earlier, although it narrowly missed the $0.52 consensus loss. CVRx Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Despite downgrading the shares to “hold,” Lake Street Capital and Craig Hallum set price targets of $3.50 and $4.00, respectively—above the current trading level—suggesting potential recovery if execution improves. The Fly analyst ratings
• Neutral Sentiment: Johnson Fistel said it is investigating whether CVRx or certain executives violated securities laws in connection with the guidance reduction and sales-execution disclosures. The announcement is an investigation notice, not a finding of wrongdoing, but it adds headline and legal risk. Johnson Fistel investigation notice
• Negative Sentiment: CVRx cut third-quarter revenue guidance to $13.5 million-$14.5 million, well below the $16.9 million consensus, and reduced full-year 2026 revenue guidance to $58 million-$60 million from an implied level near the $65.4 million consensus. Management cited slower sales productivity and Medicare Advantage-related headwinds. CVRx forecasts 2026 revenue
• Negative Sentiment: The quarterly loss slightly exceeded expectations, while CVRx continues to report deeply negative profitability, including a negative net margin and negative return on equity. Analysts responded by downgrading the stock from “buy” to “hold,” reinforcing concerns about near-term growth and execution. CVRx Q2 2026 earnings call transcript

CVRx Company Profile

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.